Stockscreener 앱 받기
12.82
1.67%
0.21
시간 외 거래:
12.83
0.010
+0.08%
전일 마감가:
$12.61
열려 있는:
$12.79
하루 거래량:
682.10K
Relative Volume:
0.49
시가총액:
$1.08B
수익:
-
순이익/손실:
$-15.28M
주가수익비율:
-25.33
EPS:
-0.5061
순현금흐름:
$-32.97M
1주 성능:
+11.48%
1개월 성능:
-20.27%
6개월 성능:
+41.35%
1년 성능:
+267.34%
1일 변동 폭
$12.59
$13.28
1주일 범위
$11.54
$13.44
52주 변동 폭
$3.4906
$26.95
Corvus Pharmaceuticals Inc Stock (CRVS) Company Profile
명칭
Corvus Pharmaceuticals Inc
전화
(650) 900-4520
주소
901 GATEWAY BLVD, THIRD FLOOR, SOUTH SAN FRANCISCO, CA
Compare CRVS vs VRTX, REGN, ARGX, ALNY, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
CRVS
Corvus Pharmaceuticals Inc
|
12.82 | 1.06B | 0 | -15.28M | -32.97M | -0.5061 |
VRTX
Vertex Pharmaceuticals Inc
|
435.92 | 110.28B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
634.42 | 66.98B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
808.61 | 50.15B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
295.50 | 39.71B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
154.89 | 32.22B | 742.00K | -1.37B | -1.07B | -7.0731 |
Corvus Pharmaceuticals Inc Stock (CRVS) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-04-17 | 개시 | Goldman | Buy |
| 2025-10-13 | 개시 | Barclays | Overweight |
| 2025-01-02 | 개시 | H.C. Wainwright | Buy |
| 2023-08-18 | 개시 | Oppenheimer | Outperform |
| 2021-12-01 | 재개 | Jefferies | Buy |
| 2021-05-27 | 개시 | Cantor Fitzgerald | Overweight |
| 2021-02-10 | 다운그레이드 | Mizuho | Buy → Neutral |
| 2019-09-12 | 개시 | Mizuho | Buy |
| 2019-05-29 | 개시 | ROTH Capital | Buy |
| 2017-08-24 | 업그레이드 | Credit Suisse | Underperform → Neutral |
| 2017-05-01 | 다운그레이드 | Credit Suisse | Neutral → Underperform |
| 2016-04-18 | 개시 | Credit Suisse | Outperform |
| 2016-04-18 | 개시 | Guggenheim | Buy |
모두보기
Corvus Pharmaceuticals Inc 주식(CRVS)의 최신 뉴스
Corvus drops after early-stage trial data for eczema therapy - MSN
Corvus Pharmaceuticals to present at major healthcare conferences in June 2026 - Pluang
Corvus (CRVS) CEO adds 6,932 shares via Miller-Horning family trust - Stock Titan
Corvus Pharmaceuticals to Present at the 2026 Jefferies Global Healthcare Conference and Goldman Sachs 47th Annual Global Healthcare Conference - marketscreener.com
Biotech Corvus heads to Jefferies and Goldman Sachs health conferences - Stock Titan
Why Corvus Pharmaceuticals (CRVS) Is Down 28.0% After Rebound‑Free Soquelitinib Phase 1 Eczema Data And What's Next - Sahm
Corvus Pharmaceuticals: The Market Is Pricing Atopic Dermatitis Success Too Early (CRVS) - Seeking Alpha
Corvus Pharmaceuticals, Inc. (CRVS) Shareholder/Analyst CallSlideshow (NASDAQ:CRVS) 2026-05-18 - Seeking Alpha
Boxer Capital’s $18 Million Corvus Pharma Bet Signals Confidence in This Biotech’s Next Phase - sharewise.com
Boxer Capital Management's New Stake in Corvus Pharmaceuticals: SEC Filing DetailsNews and Statistics - IndexBox
Corvus Pharmaceuticals, Inc.Common Stock (NQ: CRVS - FinancialContent
Point72, Steven A. Cohen show 0% stake in Corvus (CRVS) - Stock Titan
A Quick Look at Today's Ratings for Corvus Pharmaceuticals(CRVS.US), With a Forecast Between $27 to $40 - Moomoo
Sirenia/Alex Silverstein disclose 6.83M warrant shares for Corvus (NASDAQ: CRVS) - Stock Titan
Corvus Pharmaceuticals : CRVS SID Investor Meeting Presentation FINAL - marketscreener.com
Corvus Pharmaceuticals Reports Positive Final Phase 1 Results for Soquelitinib in Atopic Dermatitis at SID 2026 Annual Meeting 16 - Minichart
Corvus drops on trial data for eczema therapy (CRVS:NASDAQ) - Seeking Alpha
Corvus Pharmaceuticals Down Over 11%, On Track for Largest Percent Decrease Since March 2025 -- Data Talk - Moomoo
Corvus Pharmaceuticals Presents Soquelitinib Phase 1 Atopic Dermatitis Data at the Society for Investigative Dermatology (SID) Annual Meeting - markets.businessinsider.com
Corvus Pharmaceuticals Unveils Positive Phase 1 Dermatitis Results - TipRanks
Corvus Pharmaceuticals presents Phase 1 soquelitinib data showing durable remissions, favorable safety - TradingView
Corvus (Nasdaq: CRVS) details Phase 1 soquelitinib eczema results and next trials - Stock Titan
Drug-free remissions seen after short atopic dermatitis treatment - Stock Titan
Goldman Sachs Maintains Corvus Pharmaceuticals(CRVS.US) With Buy Rating, Maintains Target Price $40 - Moomoo
CRVS PE Ratio & Valuation, Is CRVS Overvalued - Intellectia AI
TradingKey - TradingKey
Number of shareholders of Corvus Pharmaceuticals, Inc. – NASDAQ:CRVS - TradingView
Number of shareholders of Corvus Pharmaceuticals, Inc. – TRADEGATE:C17 - TradingView
Corvus Loss, Shelf Offering and Soquelitinib Progress Might Change The Case For Investing In CRVS - Sahm
Mizuho Securities Maintains Corvus Pharmaceuticals(CRVS.US) With Buy Rating, Maintains Target Price $30 - Moomoo
Return To Losses And New Shelf Offering Might Change The Case For Investing In Corvus Pharmaceuticals (CRVS) - Yahoo Finance
Oppenheimer Maintains Corvus Pharmaceuticals(CRVS.US) With Buy Rating, Maintains Target Price $33 - Moomoo
MSN Money - MSN
Corvus: Q1 Earnings Snapshot - theheraldreview.com
Corvus Pharmaceuticals earnings up next as AD trial looms By Investing.com - Investing.com Australia
Corvus Pharmaceuticals | S-8: Initial registration statement for securities to be offered to employees pursuant to employee benefit plansmoomoo - Moomoo
Corvus (NASDAQ: CRVS) widens loss but lifts cash to $236.7M after equity raise - Stock Titan
Corvus to show eczema data backing drug-free remission potential - Stock Titan
Corvus Pharmaceuticals Provides Business Update and Reports First Quarter 2026 Financial Results - The Manila Times
Corvus Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Cash runway to 2028 as Corvus (NASDAQ: CRVS) advances soquelitinib - Stock Titan
Corvus Pharmaceuticals earnings up next as AD trial looms - Investing.com India
CRVS SEC FilingsCorvus Pharmaceu 10-K, 10-Q, 8-K Forms - Stock Titan
A Look At Corvus Pharmaceuticals (CRVS) Valuation After Adding Immunology Leader Dr. Andrew C. Chan To Its Board - Sahm
Could Corvus Pharmaceuticals’ (CRVS) New Board Appointment Reframe Its Immunology Strategy And Competitive Edge? - Sahm
Corvus Pharmaceuticals (CRVS.US) will release its earnings report after the market closes on May 7. - Moomoo
Corvus Pharmaceuticals Inc (CRVS) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.49%
0.12%
자본화:
|
볼륨(24시간):